Gynecomastia in a Transgender Boy: A Case Report

Objective: To describe the case of a 17-year-old transgender boy who experienced breast development while on testosterone, having been suppressed with a gonadotropin-releasing hormone (GnRH) agonist prior to testosterone therapy Case report: A 17-year-old transgender boy presented with breast develo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Raymond Fung, MD, BSc, FRCPC, Mary Kathleen Greenaway, MD, BSc, MPH, CCFP, FCFP, Giancarlo McEvenue, MD, FRCSC
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	gender-affirming hormone therapy gynecomastia puberty suppression testosterone therapy transgender hormone therapy Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/f5b630a1248c4d39864a2990adadb3a5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f5b630a1248c4d39864a2990adadb3a5
record_format	dspace
spelling	oai:doaj.org-article:f5b630a1248c4d39864a2990adadb3a52021-11-06T04:32:42ZGynecomastia in a Transgender Boy: A Case Report2376-060510.1016/j.aace.2021.05.003https://doaj.org/article/f5b630a1248c4d39864a2990adadb3a52021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2376060521000651https://doaj.org/toc/2376-0605Objective: To describe the case of a 17-year-old transgender boy who experienced breast development while on testosterone, having been suppressed with a gonadotropin-releasing hormone (GnRH) agonist prior to testosterone therapy Case report: A 17-year-old transgender boy presented with breast development after having been on a GnRH agonist and then testosterone since the age of 11 years, having never experienced breast development before, which was consistent with pubertal gynecomastia. A small decrease in the testosterone dose resulted in a significant reduction of gynecomastia. Despite the improvement, he went on to undergo chest surgery with the removal of the breast tissue. Discussion: Pubertal gynecomastia is a common phenomenon in the cisgender male population. However, it has not been previously described in transgender boys. The potential mechanisms for its occurrence were discussed. Conclusion: Transgender boys who undergo GnRH agonist treatment for puberty suppression and subsequently receive testosterone therapy for puberty induction may develop gynecomastia. Judicious adjustment of the testosterone therapy may lead to an improvement.Raymond Fung, MD, BSc, FRCPCMary Kathleen Greenaway, MD, BSc, MPH, CCFP, FCFPGiancarlo McEvenue, MD, FRCSCElsevierarticlegender-affirming hormone therapygynecomastiapuberty suppressiontestosterone therapytransgender hormone therapyDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENAACE Clinical Case Reports, Vol 7, Iss 6, Pp 350-352 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	gender-affirming hormone therapy gynecomastia puberty suppression testosterone therapy transgender hormone therapy Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	gender-affirming hormone therapy gynecomastia puberty suppression testosterone therapy transgender hormone therapy Diseases of the endocrine glands. Clinical endocrinology RC648-665 Raymond Fung, MD, BSc, FRCPC Mary Kathleen Greenaway, MD, BSc, MPH, CCFP, FCFP Giancarlo McEvenue, MD, FRCSC Gynecomastia in a Transgender Boy: A Case Report
description	Objective: To describe the case of a 17-year-old transgender boy who experienced breast development while on testosterone, having been suppressed with a gonadotropin-releasing hormone (GnRH) agonist prior to testosterone therapy Case report: A 17-year-old transgender boy presented with breast development after having been on a GnRH agonist and then testosterone since the age of 11 years, having never experienced breast development before, which was consistent with pubertal gynecomastia. A small decrease in the testosterone dose resulted in a significant reduction of gynecomastia. Despite the improvement, he went on to undergo chest surgery with the removal of the breast tissue. Discussion: Pubertal gynecomastia is a common phenomenon in the cisgender male population. However, it has not been previously described in transgender boys. The potential mechanisms for its occurrence were discussed. Conclusion: Transgender boys who undergo GnRH agonist treatment for puberty suppression and subsequently receive testosterone therapy for puberty induction may develop gynecomastia. Judicious adjustment of the testosterone therapy may lead to an improvement.
format	article
author	Raymond Fung, MD, BSc, FRCPC Mary Kathleen Greenaway, MD, BSc, MPH, CCFP, FCFP Giancarlo McEvenue, MD, FRCSC
author_facet	Raymond Fung, MD, BSc, FRCPC Mary Kathleen Greenaway, MD, BSc, MPH, CCFP, FCFP Giancarlo McEvenue, MD, FRCSC
author_sort	Raymond Fung, MD, BSc, FRCPC
title	Gynecomastia in a Transgender Boy: A Case Report
title_short	Gynecomastia in a Transgender Boy: A Case Report
title_full	Gynecomastia in a Transgender Boy: A Case Report
title_fullStr	Gynecomastia in a Transgender Boy: A Case Report
title_full_unstemmed	Gynecomastia in a Transgender Boy: A Case Report
title_sort	gynecomastia in a transgender boy: a case report
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/f5b630a1248c4d39864a2990adadb3a5
work_keys_str_mv	AT raymondfungmdbscfrcpc gynecomastiainatransgenderboyacasereport AT marykathleengreenawaymdbscmphccfpfcfp gynecomastiainatransgenderboyacasereport AT giancarlomcevenuemdfrcsc gynecomastiainatransgenderboyacasereport
_version_	1718443894444654592

Gynecomastia in a Transgender Boy: A Case Report

Ejemplares similares